论文部分内容阅读
目的探讨核苷类抗病毒治疗对慢性乙型肝炎(以下简称“慢乙肝”)相关性肝癌患者术后预后的影响。方法回顾性分析2010年3月至2014年3月间浙江省宁波区奉化人民医院收住的100例乙型肝炎病毒-脱氧核糖核酸(HBV-DNA)阳性的慢乙肝相关性肝癌术后患者,50例对照组采用单纯手术切除或加肝动脉化疗栓塞术(TACE)治疗,50例治疗组采用手术切除或加TACE术后核苷类抗病毒治疗。结果治疗2年和3年结果显示,治疗组和对照组HBV-DNA清除率分别为100%和0%,两组差异有统计学意义(P<0.01)。治疗组2年和3年复发率均明显低于对照组。治疗组2年及3年生存率分别为50.0%及46.0%,而对照组分别为30.0%及24.0%,两组差异有统计学意义(P<0.05)。结论核苷类药物抗病毒治疗对慢乙肝相关性肝癌术后患者能抑制HBV-DNA复制,最大限度的延缓复发,提高患者生存率。
Objective To investigate the effect of nucleoside antiviral therapy on postoperative prognosis of patients with hepatocellular carcinoma associated with chronic hepatitis B (hereinafter referred to as “chronic hepatitis B”). Methods A retrospective analysis of 100 patients with hepatitis B virus DNA (HBV-DNA) -positive chronic hepatitis B-related liver cancer admitted to Fenghua People’s Hospital of Ningbo, Zhejiang Province from March 2010 to March 2014 was retrospectively analyzed. Fifty patients in the control group were treated with simple surgical resection or transcatheter arterial chemoembolization (TACE). Fifty patients in the control group were treated with surgical resection or TACE plus nucleoside antiviral therapy. Results The results of two and three years of treatment showed that the HBV-DNA clearance rates in the treatment group and the control group were 100% and 0%, respectively, with significant differences between the two groups (P <0.01). The two-year and three-year relapse rates in the treatment group were significantly lower than those in the control group. The two-year and three-year survival rates in the treatment group were 50.0% and 46.0%, respectively, while those in the control group were 30.0% and 24.0%, respectively. There was significant difference between the two groups (P <0.05). Conclusion Nucleoside anti-virus therapy can inhibit HBV-DNA replication in patients with chronic hepatitis B-related hepatocellular carcinoma (HCC) postoperatively, and can delay relapse to the maximum extent and improve patient survival rate.